Replication-defective mutants of mouse cytomegalovirus protect against wild-type virus challenge

T A Gill1, P J Morley, C Sweet

  • 1Microbial Molecular Genetics and Cell Biology research Group, School of Biosciences, The University of Birmingham, Birmingham, B15 2TT.

Journal of Medical Virology
|September 26, 2000
PubMed

Insights

Five temperature-sensitive murine cytomegalovirus mutants were analyzed for replication blocks. Mutants tsm20 and tsm30 showed potential as vaccine models due to induced protection against virulent virus challenges.

Area of Science:

  • Virology
  • Immunology
  • Genetics

Background:

  • Murine cytomegalovirus (MCMV) temperature-sensitive mutants (tsm) are valuable tools for studying viral replication.
  • Previous studies identified five MCMV tsm mutants (tsm9, tsm13, tsm20, tsm22, tsm30) that do not produce infectious virus in mice.

Purpose of the Study:

  • To determine the replication block stage of five MCMV temperature-sensitive mutants in vitro.
  • To investigate the in vivo replication and immunogenic potential of selected MCMV tsm mutants.

Main Methods:

  • Transcriptional analysis of four temporally regulated genes (IE-1, E-1, gB, gH) using semi-quantitative reverse transcription polymerase chain reaction (RT-PCR).
  • Electron microscopic analysis of infected cells at permissive (33°C) and non-permissive (39-40°C) temperatures.
  • In vivo replication and transcription studies in infected mice, followed by challenge experiments.

Main Results:

  • Replication blocks varied from immediate-early (tsm22) to late phases (tsm13) and maturation/capsid formation (tsm9, tsm20, tsm30).
  • Mutants tsm20 and tsm30 exhibited no infectious virus production in mice but showed gene transcription in various tissues.
  • Mice infected with tsm20 or tsm30 were protected against virulent MCMV challenge, with tsm30 also providing protection against lethal challenge.

Conclusions:

  • The study elucidates the distinct replication defects of MCMV temperature-sensitive mutants.
  • Mutants tsm20 and tsm30 demonstrate potential as live vaccine candidates for inducing protective immunity against MCMV infection.